Revumenib

4 trials 2 recruiting Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

2 Recruiting

1 Completed trials

3 Sponsors

20 Countries

Phase III

Phase II

Phase I (FiH)

Phase III: 2 Phase II: 1 Phase I (FiH): 1

Sponsors using this IMP

Syndax Pharmaceuticals Inc. 2 Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting 1 Pediatric Research International GmbH 1

All trials

4 total

Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukem… Pending

2025-521390-14-00 Phase II 8 countries Pediatric Research International GmbH
Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting

2025-522279-27-00 Phase III 13 countries Syndax Pharmaceuticals Inc.
A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML… Recruiting

2024-512733-32-00 Phase III 14 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
A study to investigate the short- and long-term safety and tolerability of the drug SNDX-5613 in Patients with Relapsed/Refractory Leukemias… Ended

2024-513759-34-00 Phase I (FiH) 6 countries Syndax Pharmaceuticals Inc.

Showing 1–4 of 4 trials

← All drugs A–Z